Company / Profit Margin
Matinas BioPharma Holdings, Inc. Profit Margin History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-658.6%
FY2023
5-year range
-70554.5% / -658.6%
FY2019-FY2023
Trend
+99.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -70554.5% to -658.6% over the past 2 years.
Based on SEC 10-K filings.
-658.6% in FY2023 with a 5-year CAGR of +9687.3%.
Improved from -70554.5% to -658.6% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- +13518.4pp
- 5-Year Change
- +9687.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, profit margin increased 99.1% year-over-year.
- Lowest profit margin in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -658.6% | +99.1% |
| FY2022 | -70554.5% | +0.0% |
| FY2021 | -70554.5% | -397.7% |
| FY2020 | -14177.0% | -20.5% |
| FY2019 | -11760.4% | -13.7% |
| FY2018 | -10345.9% | -120.3% |
| FY2017 | -4697.0% | - |
| FY2016 | - | - |
| FY2015 | -4697.0% | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026